MATCHPOINT THERAPEUTICS ANNOUNCES $150 MILLION SERIES B FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS ORAL SMALL MOLECULES FOR AUTOIMMUNE AND INFLAMMATORY DISEASES

Reuters · 2d ago

Please log in to view news